

Product Data Sheet

Product Name: NN1177 TFA

Cat. No.: GC72097

Chemical Properties

Cas. No.

Formula $C_{206}H_{323}N_{51}O_{66}.xC_2HF_3O_2$ M.Wt 4570.07 (free base)

Solubility H_2O : 100 mg/mL (Need ultrasonic) Storage Sealed storage, away from moisture and light

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure

His-{Aib}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-
Leu-Ser-Lys-Tyr-Leu-Glu-Ser-Lys-Arg-
Ala-Arg-Glu-Phe-Val-Gln-Trp-Leu-Leu-
{Lys(γ Glu- γ Glu-Ser-Glu-Ser- γ Glu- γ Glu-
C₁₈ diacid))-Thr-NH₂ (TFA)

Background

NN1177 (NNC9204-1177) TFA is a long-acting GLP-1/glucagon receptor co-agonist. NN1177 TFA can induce a dose-dependent body weight loss in diet-induced obese (DIO) mice.

NN1177 (100 nM, 3 days) TFA reduces CYP3A4 mRNA expression (57.2-71.7%) and activity (18.5-51.5%) in freshly isolated human hepatocytes^[3].

NN1177 (3 or 5 nmol/kg, s.c.) TFA induces body weight loss, loss of fat mass, and improvement in

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

glucose tolerance in diet-induced obese (DIO) mice^[1].

NN1177 (0.75-4 nmol/kg, s.c., once daily, 8 weeks) TFA reduces liver fat and inflammatory and fibrosis relevant biomarkers in C57Bl/6 mice fed a fructose and high fat rich diet (NASH model)^[2].

References:

[1]. Simonsen L, et al. Preclinical evaluation of a protracted GLP-1/glucagon receptor co-agonist: Translational difficulties and pitfalls. PLoS One. 2022 Mar 4;17(3):e0264974.

[2]. Monfeuga T, et al. Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon agonism in NASH patients. Mol Metab. 2023 Dec 7;79:101850.

[3]. Säll C, et al. In vitro CYP450 enzyme down-regulation by GLP-1/glucagon co-agonist does not translate to observed drug-drug interactions in the clinic. Drug Metab Dispos. 2022 Jun 9:DMD-AR-2022-000865.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA